Short Bowel Syndrome – Pipeline Review, H1 2012

Date: May 28, 2012
Pages: 38
Price:
US$ 500.00 US$ 450.00
Offer valid until December 31, 2014!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: S7F55ECFCBAEN
Leaflet:

Download PDF Leaflet

Short Bowel Syndrome – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Short Bowel Syndrome - Pipeline Review, H1 2012', provides an overview of the Short Bowel Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Short Bowel Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Short Bowel Syndrome. 'Short Bowel Syndrome - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Short Bowel Syndrome.
  • A review of the Short Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Short Bowel Syndrome pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Short Bowel Syndrome.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Short Bowel Syndrome pipeline depth and focus of Short Bowel Syndrome therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Keywords

Short Bowel Syndrome Therapeutic Products under Development, Key Players in Short Bowel Syndrome Therapeutics, Short Bowel Syndrome Pipeline Overview, Short Bowel Syndrome Pipeline, Short Bowel Syndrome Pipeline Assessment
Introduction
Global Markets Direct Report Coverage
Short Bowel Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Short Bowel Syndrome
Short Bowel Syndrome Therapeutics under Development by Companies
Short Bowel Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Short Bowel Syndrome Therapeutics – Products under Development by Companies
Short Bowel Syndrome Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Short Bowel Syndrome Therapeutics Development
NPS Pharmaceuticals, Inc.
7TM PHARMA A/S
Short Bowel Syndrome – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
GATTEX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TM30339 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RotaTeq - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Short Bowel Syndrome Therapeutics – Drug Profile Updates
Short Bowel Syndrome – Product Development Milestones
Featured News & Press Releases
May 03, 2012: NPS Pharma Reports Positive Update From STEPS 2 Study Of Gattex For Treatment Of Short Bowel Syndrome
Jan 31, 2012: NPS Pharmaceuticals Announces FDA Acceptance Of New Drug Application For GATTEX For Treatment Of Adult Short Bowel Syndrome
Dec 01, 2011: NPS Completes Submission Of NDA For GATTEX In Adult Short Bowel Syndrome
Nov 07, 2011: Tengion Organ Regeneration Platform Technology Demonstrates Ability To Regenerate Small Intestine In Preclinical Models
Oct 31, 2011: NPS's Phase III GATTEX Data Highlight Potential New Treatment For Adults With Short Bowel Syndrome
Aug 18, 2011: NPS Pharmaceuticals Submits Chemistry, Manufacturing And Controls Section Of New Drug Application For GATTEX
May 10, 2011: NPS's GATTEX Shown To Reduce Parenteral Support Volume In Patients With Adult Short Bowel Syndrome
Mar 28, 2011: Nycomed Submits European MAA For Teduglutide
Jan 31, 2011: NPS Reports Positive Results Of Phase III Pivotal Study For GATTEX In Adult SBS
Jan 10, 2011: NPS Completes Treatment Phase In STEPS Registration Study Of GATTEX In Short Bowel Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Short Bowel Syndrome, H1 2012
Products under Development for Short Bowel Syndrome – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
NPS Pharmaceuticals, Inc., H1 2012
7TM PHARMA A/S, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Short Bowel Syndrome Therapeutics – Drug Profile Updates

LIST OF FIGURES

Number of Products under Development for Short Bowel Syndrome, H1 2012
Products under Development for Short Bowel Syndrome – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Short Bowel Syndrome - Pipeline Review, Q2 2011 US$ 450.00 May, 2011 · 35 pages
Irritable Bowel Syndrome - Pipeline Review, Q1 2011 US$ 450.00 Feb, 2011 · 67 pages
Frozen Shoulder Syndrome - Pipeline Review, Q4 2010 US$ 450.00 Nov, 2010 · 50 pages
Sjogren's Syndrome - Pipeline Review, Q4 2010 US$ 450.00 Nov, 2010 · 50 pages

Ask Your Question

Short Bowel Syndrome – Pipeline Review, H1 2012
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: